Kininogen Recombinant Protein | KNG1 recombinant protein

Purified recombinant Kininogen protein

Cat. Num. AAA5308781

• Gene Names: KNG1; BK; BDK; KNG
• Applications: ELISA, SDS-Page, Western Blot
• Purity: > 90% pure
• Synonyms: Kininogen; Purified recombinant Kininogen protein; Kininogen protein; KNG1 recombinant protein

• Host: Human
• Purity/Purification: > 90% pure
• Form/Format: Supplied in liquid form in 20mM Tris-Hcl, 0.5MNaCl, 10% glycerin (pH 8.0) and 200 mM Imidazole
• Sequence Length: 427

• Applicable Applications for KNG1 recombinant protein: ELISA (EIA), SDS-PAGE, Western Blot (WB)
• Expression: E Coli
• Preparation and Storage: Store at 4 degree C in a working aliquot for 1 week. For long term storage, aliquot and freeze at -20 to -80 degree C, avoid repeat freeze/thaw cycles.

SDS-Page

()

Product Categories/Family for KNG1 recombinant protein

Proteases; Inhibitors; & Enzymes

NCBI and Uniprot Product Information

• NCBI GI #: 386853
• NCBI GeneID: 3827
• Molecular Weight: 43,822 Da
• NCBI Official Full Name: kininogen
• NCBI Official Synonym Full Names: kininogen 1
• NCBI Official Symbol: KNG1
• NCBI Official Synonym Symbols: BK; BDK; KNG
• NCBI Protein Information: kininogen-1
• UniProt Protein Name: Kininogen-1
• Protein Family: Kininogen
• UniProt Gene Name: KNG1
• UniProt Synonym Gene Names: BDK; KNG; HMWK

NCBI Description

This gene uses alternative splicing to generate two different proteins- high molecular weight kininogen (HMWK) and low molecular weight kininogen (LMWK). HMWK is essential for blood coagulation and assembly of the kallikrein-kinin system. Also, bradykinin, a peptide causing numerous physiological effects, is released from HMWK. Bradykinin also functions as an antimicrobial peptide with antibacterial and antifungal activity. In contrast to HMWK, LMWK is not involved in blood coagulation. Three transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Nov 2014]

Uniprot Description

1 Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.